ArticleOncotarget2016

A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.

Chiao-Chieh Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.